Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 143, Issue 5, 2012, Pages 1069-1076

  Graham, Eric M ^a   Atz, Andrew M ^a   Gillis, Jenna ^a   DeSantis, Stacia M ^b   Haney, A Lauren ^b   Deardorff, Rachael L ^a   Uber, Walter E ^b   Reeves, Scott T ^a   McGowan Jr , Francis X ^a   Bradley, Scott M ^a   Spinale, Francis G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; C REACTIVE PROTEIN; DOPAMINE; INOTROPIC AGENT; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; METHYLPREDNISOLONE; MILRINONE; RECOMBINANT ACTIVATED BLOOD CLOTTING FACTOR 7; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL (TOPIC); COURSE EVALUATION; CRYOPRECIPITATE; CYTOKINE PRODUCTION; ERYTHROCYTE TRANSFUSION; FEMALE; HEART SURGERY; HOSPITAL COST; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN SURGERY; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SHUNT THROMBOSIS; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; WOUND CLOSURE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CHI-SQUARE DISTRIBUTION; CYTOKINES; ERYTHROCYTE TRANSFUSION; FACTOR VIIA; FEMALE; HEART DEFECTS, CONGENITAL; HOSPITAL CHARGES; HUMANS; INFANT, NEWBORN; INFLAMMATION MEDIATORS; INTERLEUKIN-2; MALE; PLATELET TRANSFUSION; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SOUTH CAROLINA; TIME FACTORS; TRANEXAMIC ACID; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859751812     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2011.08.051     Document Type: Article

References (25)

1. Hickey E, Karamlou T, You J, Ungerleider RM. Effects of circuit miniaturization in reducing inflammatory response to infant cardiopulmonary bypass by elimination of allogeneic blood products. Ann Thorac Surg. 2006;81:S2367-72. (Pubitemid 43775526)
2. Ugaki S, Honjo O, Nakakura M, Douguchi T, Itagaki A, Yokoyama N, et al. Transfusion-free neonatal cardiopulmonary bypass using a TinyPump. Ann Thorac Surg. 2010;90:1615-21.
3. Salvin JW, Scheurer MA, Laussen PC,Wypij D, Polito A, Bacha EA, et al. Blood transfusion after pediatric cardiac surgery is associated with prolonged hospital stay. Ann Thorac Surg. 2011;91:204-10.
4. Kipps AK,Wypij D, Thiagarajan RR, Bacha EA, Newburger JW. Blood transfusion is associated with prolonged duration of mechanical ventilation in infants undergoing reparative cardiac surgery. Pediatr Crit Care Med. 2011;12:52-6.
5. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-65. (Pubitemid 43145060)
6. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319-31. (Pubitemid 351749156)
7. Pasquali SK, Hall M, Li JS, Peterson ED, Jaggers J, Lodge AJ, et al. Safety of aprotinin in congenital heart operations: results from a large multicenter database. Ann Thorac Surg. 2010;90:14-21.
8. GuzzettaNA, Evans FM,Rosenberg ES, Fazlollah TM,BakerMJ,WilsonEC, et al. The impact of aprotinin on postoperative renal dysfunction in neonates undergoing cardiopulmonary bypass: a retrospective analysis. Anesth Analg. 2009;108:448-55.
9. Breuer T, Martin K,Wilhelm M,Wiesner G, Schreiber C, Hess J, et al. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg. 2009;35:167-71.
10. Backer CL, Kelle AM, Stewart RD, Suresh SC, Ali FN, Cohn RA, et al. Aprotinin is safe in pediatric patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2007;134:1421-6.
11. Manrique A, Jooste EH, Kuch BA, Lichtenstein SE, Morell V, Munoz R, et al. The association of renal dysfunction and the use of aprotinin in patients undergoing congenital cardiac surgery requiring cardiopulmonary bypass. Anesth Analg. 2009;109:45-52.
12. Hsia TY, McQuinn TC, Mukherjee R, Deardorff RL, Squires JE, Stroud RE, et al. Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery. Ann Thorac Surg. 2010;89:1843-52.
13. Iwata Y, Okamura T, Ishibashi N, Zurakowski D, Lidov HG, Jonas RA. Optimal dose of aprotinin for neuroprotection and renal function in a piglet survival model. J Thorac Cardiovasc Surg. 2009;137:1521-9.
14. Ishibashi N, Iwata Y, Zurakowski D, Lidov HG, Jonas RA. Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass. Perfusion. 2009;24:99-105.
15. Later AF, Maas JJ, Engbers FH, Versteegh MI, Bruggemans EF, Dion RA, et al. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial. Eur J Cardiothorac Surg. 2009;36:322-9.
16. Karkouti K,Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg. 2010;110:21-9.
17. Dietrich W. Aprotinin: 1 year on. Curr Opin Anaesthesiol. 2009;22:121-7.
18. Graham EM, Atz AM, Butts RJ, Baker NL, Zyblewski SC, Deardorff RL, et al. Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg. 2011 May 19 [Epub ahead of print.].
19. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107:996-1002. (Pubitemid 36258723)
20. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
21. Williams GD, Ramamoorthy C, Pentcheva K, Boltz MG, Kamra K, Reddy VM. A randomized, controlled trial of aprotinin in neonates undergoing open-heart surgery. Paediatr Anaesth. 2008;18:812-9.
22. Verma YS, Chauhan S, Bisoi AK, Gharde P, Kiran U, Das SN. Comparison of three dose regimens of aprotinin in infants undergoing the arterial switch operation. Ann Card Anaesth. 2010;13:110-5.
23. Arnold DM, Fergusson DA, Chan AK, Cook RJ, Fraser GA, Lim W, et al. Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth Analg. 2006;102:731-7.
24. Koster A, Schirmer U. Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. Curr Opin Anaesthesiol. 2011;24:92-7.
25. McEvoy MD, Reeves ST, Reves JG, Spinale FG. Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg. 2007;105:949-62.